New Research-Grade 5-Amino-1MQ for NNMT Studies
Umbrella Labs has introduced 5-amino-1MQ, a research-grade compound designed to aid scientists in understanding NNMT (nicotinamide N-methyltransferase) pathways involved in metabolic regulation. This development aims to support the rigor and reproducibility of NNMT-pathway studies.
Key Research Points
- Novel Research Chemical: 5-amino-1MQ is now available as a research-use-only liquid, supported by comprehensive documentation.
- Focus on NNMT: The compound is a tool for studying NNMT, an enzyme involved in methyl donor utilization and NAD+ salvage pathways.
- Documentation-First Approach: Umbrella Labs emphasizes consistent handling guidance to support data comparability across experiments.
- Preclinical Research Context: A 2024 study in Nature Scientific Reports reported that NNMT inhibition appeared to mimic exercise-related metabolic changes in aged mouse muscle; findings are preclinical and have not been established in humans.
Supporting NNMT Research
Umbrella Labs has launched 5-amino-1MQ, a specialized chemical probe intended for laboratory research. This compound is designed to help researchers investigate the role of nicotinamide N-methyltransferase (NNMT) in metabolic processes. NNMT is a key enzyme that influences how the body manages methyl donors and nicotinamide, impacting pathways related to energy metabolism and NAD+ salvage.
The company highlights that 5-amino-1MQ is provided with a strong emphasis on documentation and consistent handling guidance. This approach aims to address common challenges in research, such as variability caused by compound stability, preparation inconsistencies, or assay interference. By providing detailed characterization and workflow support, Umbrella Labs seeks to support the reliability and interpretability of experimental results.
Preclinical Findings in Aged Mouse Models
Recent research has examined NNMT inhibitors, including 5-amino-1MQ (referred to as 5A-1MQ in the study), in the context of muscle biology and aging. A study published in Nature Scientific Reports (Narasimhan et al., 2024) indicated that inhibiting NNMT appeared to mimic exercise-related metabolic changes in aged mouse muscle. These are observations from a preclinical aged-mouse model and have not been replicated in human studies.
The study also observed that NNMT inhibition, both alone and in combination with exercise, was associated with changes in muscle strength and function measurements in aged mice. Researchers note these observations may warrant further investigation as a model for studying muscle metabolism. All findings are from preclinical models only.
Sources
- Umbrella Labs: Research Use Only 5-Amino-1MQ Liquid Program for NNMT and NAD+ Salvage Studies, Yahoo Finance.
- Narasimhan et al. (2024): NNMT inhibition and exercise in aged mice — Nature Scientific Reports, Nature.
For laboratory research use only. Not for human or veterinary use. Not a medicinal product.
Frequently asked questions
What is the proposed mechanism by which 5-amino-1MQ acts on NNMT in preclinical models?
5-amino-1MQ functions as a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyses the methylation of nicotinamide using S-adenosylmethionine as a methyl donor, thereby influencing NAD⁺ salvage pathways and methyl donor availability. In preclinical aged-mouse models, NNMT inhibition was associated with altered metabolic pathway activity in skeletal muscle tissue (Narasimhan et al., 2024, Nature Scientific Reports). This compound is preclinical (animal/in vitro) research only and no established human data exist.
What does the 2024 Narasimhan et al. study reveal about NNMT inhibition in aged mouse models, and what are its limitations?
The study reported that NNMT inhibition appeared to mimic exercise-related metabolic changes in aged mouse skeletal muscle and was associated with changes in muscle strength and function measurements in that model. As an animal model study, the findings are subject to the inherent limitations of species-specific physiology and cannot be extrapolated to human biology without further investigation. All findings are preclinical (animal/in vitro) research only, with no established human data.
What documentation and quality assurances should researchers expect with a research-grade 5-amino-1MQ compound?
Research-grade 5-amino-1MQ should be accompanied by certificates of analysis (CoA), purity data (typically assessed via HPLC and mass spectrometry), and handling guidance addressing compound stability and solubility to minimise experimental variability. Consistent characterisation documentation is critical for data comparability across independent laboratory experiments. This compound is supplied as a research-use-only (RUO) compound and is not for human or veterinary use.
How does NNMT's role in the NAD⁺ salvage pathway make it a relevant target for metabolic research models?
NNMT consumes nicotinamide as a substrate, which competes with the NAD⁺ salvage pathway; consequently, its inhibition in experimental models has been associated with shifts in intracellular NAD⁺ availability and methyl donor pools. These biochemical interactions make NNMT a point of interest for in vitro and animal model studies exploring energy metabolism. Research employing 5-amino-1MQ as a chemical probe is solely for use by qualified researchers in preclinical settings.
What is the regulatory and research-use status of 5-amino-1MQ?
5-amino-1MQ is classified as a research-use-only (RUO) compound and is not authorised as a medicinal product. It is not for human or veterinary use, and no approved regulatory indication exists for this compound in any jurisdiction. Its use is appropriate solely within controlled laboratory settings by qualified researchers investigating NNMT biology in preclinical models.
